IL-12 promotes myeloid-derived suppressor cell recruitment and bacterial persistence during Staphylococcus aureus orthopedic implant infection

Journal of Immunology

Volumn 194, Issue 8, 2015, Pages 3861-3872

  Heim, Cortney E ^a   Vidlak, Debbie ^a   Scherr, Tyler D ^a   Hartman, Curtis W ^b   Garvin, Kevin L ^b   Kielian, Tammy ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CXCL2 CHEMOKINE; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 12P35; INTERLEUKIN 12P40; INTERLEUKIN 1BETA; RANTES; TUMOR NECROSIS FACTOR ALPHA; IL12A PROTEIN, MOUSE;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL CLEARANCE; BACTERIAL LOAD; BIOFILM; CONTROLLED STUDY; CYTOKINE PRODUCTION; HUMAN; HUMAN TISSUE; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC INFILTRATION; MACROPHAGE MIGRATION; MALE; MONOCYTE; MOUSE; MYELOID DERIVED SUPPRESSOR CELL; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PERIPROSTHETIC JOINT INFECTION; PRIORITY JOURNAL; PROSTHESIS LOOSENING; REOPERATION; SOFT TISSUE INFLAMMATION; STAPHYLOCOCCUS EPIDERMIDIS; STAPHYLOCOCCUS INFECTION; SUPPRESSOR CELL; T LYMPHOCYTE; ADVERSE EFFECTS; ANIMAL; DISEASE MODEL; GENETICS; IMMUNOLOGY; INFECTION; KNOCKOUT MOUSE; NEUTROPHIL; ORTHOPEDIC SURGERY; PATHOLOGY; PHYSIOLOGY; PROSTHESES AND ORTHOSES; STAPHYLOCOCCUS AUREUS;

ANIMALS; BIOFILMS; DISEASE MODELS, ANIMAL; HUMANS; INTERLEUKIN-12 SUBUNIT P35; INTERLEUKIN-12 SUBUNIT P40; MALE; MICE; MICE, KNOCKOUT; MONOCYTES; NEUTROPHIL INFILTRATION; NEUTROPHILS; ORTHOPEDIC PROCEDURES; PROSTHESES AND IMPLANTS; PROSTHESIS-RELATED INFECTIONS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 84927587945     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1402689     Document Type: Article

References (69)

1. Del Pozo, J. L., and R. Patel. 2009. Clinical practice: infection associated with prosthetic joints. N. Engl. J. Med. 361:787-794.
2. Kurtz, S. M., E. Lau, J. Schmier, K. L. Ong, K. Zhao, and J. Parvizi. 2008. Infection burden for hip and knee arthroplasty in the United States. J. Arthroplasty 23:984-991.
3. Rao, N., B. Cannella, L. S. Crossett, A. J. Yates, Jr., and R. McGough, III. 2008. A preoperative decolonization protocol for Staphylococcus aureus prevents orthopaedic infections. Clin. Orthop. Relat. Res. 466:1343-1348.
4. Goyal, N., A. Miller, M. Tripathi, and J. Parvizi. 2013. Methicillin-resistant Staphylococcus aureus (MRSA): colonisation and pre-operative screening. Bone Joint J. 95-B:4-9.
5. Kim, D. H., M. Spencer, S. M. Davidson, L. Li, J. D. Shaw, D. Gulczynski, D. J. Hunter, J. F. Martha, G. B. Miley, S. J. Parazin, et al. 2010. Institutional prescreening for detection and eradication of methicillin-resistant Staphylococcus aureus in patients undergoing elective orthopaedic surgery. J. Bone Joint Surg. Am. 92:1820-1826.
6. Hanke, M. L., and T. Kielian. 2012. Deciphering mechanisms of staphylococcal biofilm evasion of host immunity. Front. Cell. Infect. Microbiol. 2:62.
7. Scherr, T. D., C. E. Heim, J. M. Morrison, and T. Kielian. 2014. Hiding in plain sight: interplay between staphylococcal biofilms and host immunity. Front. Immunol. 5:37.
8. Otto, M. 2008. Staphylococcal biofilms. Curr. Top. Microbiol. Immunol. 322:207-228.
9. Zimmerli, W., A. Trampuz, and P. E. Ochsner. 2004. Prosthetic-joint infections. N. Engl. J. Med. 351:1645-1654.
10. Lew, D. P., and F. A. Waldvogel. 2004. Osteomyelitis. Lancet 364:369-379.
11. Fitzgerald, R. H., Jr. 1983. Experimental osteomyelitis: description of a canine model and the role of depot administration of antibiotics in the prevention and treatment of sepsis. J. Bone Joint Surg. Am. 65:371-380.
12. Salgado, C. D., S. Dash, J. R. Cantey, and C. E. Marculescu. 2007. Higher risk of failure of methicillin-resistant Staphylococcus aureus prosthetic joint infections. Clin. Orthop. Relat. Res. 461:48-53.
13. Walls, R. J., S. J. Roche, A. O'Rourke, and J. P. McCabe. 2008. Surgical site infection with methicillin-resistant Staphylococcus aureus after primary total hip replacement. J. Bone Joint Surg. Br. 90:292-298.
14. Schwarzkopf, R., D. Oh, E. Wright, D. M. Estok, and J. N. Katz. 2013. Treatment failure among infected periprosthetic patients at a highly specialized revision TKA referral practice. Open Orthop. J. 7:264-271.
15. García-Alvarez, F., M. Navarro-Zorraquino, A. Castro, J. M. Grasa, C. Pastor, M. Monzón, A. Martínez, I. García-Alvarez, J. Castillo, and R. Lozano. 2009. Effect of age on cytokine response in an experimental model of osteomyelitis. Biogerontology 10:649-658.
16. Yoshii, T., S. Magara, D. Miyai, H. Nishimura, E. Kuroki, S. Furudoi, T. Komori, and C. Ohbayashi. 2002. Local levels of interleukin-1beta, -4, -6 and tumor necrosis factor alpha in an experimental model of murine osteomyelitis due to Staphylococcus aureus. Cytokine 19:59-65.
17. Claro, T., A. Widaa, C. McDonnell, T. J. Foster, F. J. O'Brien, and S. W. Kerrigan. 2013. Staphylococcus aureus protein A binding to osteoblast tumour necrosis factor receptor 1 results in activation of nuclear factor kappa B and release of interleukin-6 in bone infection. Microbiology 159:147-154.
18. Horst, S. A., V. Hoerr, A. Beineke, C. Kreis, L. Tuchscherr, J. Kalinka, S. Lehne, I. Schleicher, G. Köhler, T. Fuchs, et al. 2012. A novel mouse model of Staphylococcus aureus chronic osteomyelitis that closely mimics the human infection: an integrated view of disease pathogenesis. Am. J. Pathol. 181:1206-1214.
19. Bernthal, N. M., J. R. Pribaz, A. I. Stavrakis, F. Billi, J. S. Cho, R. I. Ramos, K. P. Francis, Y. Iwakura, and L. S. Miller. 2011. Protective role of IL-1b against postarthroplasty Staphylococcus aureus infection. J. Orthop. Res. 29:1621-1626.
20. Prabhakara, R., J. M. Harro, J. G. Leid, M. Harris, and M. E. Shirtliff. 2011. Murine immune response to a chronic Staphylococcus aureus biofilm infection. Infect. Immun. 79:1789-1796.
21. Prabhakara, R., J. M. Harro, J. G. Leid, A. D. Keegan, M. L. Prior, and M. E. Shirtliff. 2011. Suppression of the inflammatory immune response prevents the development of chronic biofilm infection due to methicillin-resistant Staphylococcus aureus. Infect. Immun. 79:5010-5018.
22. Heim, C. E., D. Vidlak, T. D. Scherr, J. A. Kozel, M. Holzapfel, D. E. Muirhead, and T. Kielian. 2014. Myeloid-derived suppressor cells contribute to Staphylococcus aureus orthopedic biofilm infection. J. Immunol. 192:3778-3792.
23. Goriely, S., M. F. Neurath, and M. Goldman. 2008. How microorganisms tip the balance between interleukin-12 family members. Nat. Rev. Immunol. 8:81-86.
24. Trinchieri, G. 2003. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. 3:133-146.
25. Cooper, A. M., and S. A. Khader. 2007. IL-12p40: an inherently agonistic cytokine. Trends Immunol. 28:33-38.
26. Gillessen, S., D. Carvajal, P. Ling, F. J. Podlaski, D. L. Stremlo, P. C. Familletti, U. Gubler, D. H. Presky, A. S. Stern, and M. K. Gately. 1995. Mouse interleukin-12 (IL-12) p40 homodimer: a potent IL-12 antagonist. Eur. J. Immunol. 25:200-206.
27. Wang, X., V. L. Wilkinson, F. J. Podlaski, C. Wu, A. S. Stern, D. H. Presky, and J. Magram. 1999. Characterization of mouse interleukin-12 p40 homodimer binding to the interleukin-12 receptor subunits. Eur. J. Immunol. 29:2007-2013.
28. Scherr, T. D., K. E. Lindgren, C. R. Schaeffer, M. L. Hanke, C. W. Hartman, and T. Kielian. 2014. Mouse model of post-arthroplasty Staphylococcus epidermidis joint infection. Methods Mol. Biol. 1106:173-181.
29. Marigo, I., E. Bosio, S. Solito, C. Mesa, A. Fernandez, L. Dolcetti, S. Ugel, N. Sonda, S. Bicciato, E. Falisi, et al. 2010. Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor. Immunity 32:790-802.
30. Herzenberg, L. A., J. Tung, W. A. Moore, L. A. Herzenberg, and D. R. Parks. 2006. Interpreting flow cytometry data: a guide for the perplexed. Nat. Immunol. 7:681-685.
31. Steckelberg, J. M., and D. R. Osmon. 2000. Prosthetic joint infections. In Infections Associated with Indwelling Medical Devices, 3rd Ed. F. A. Waldvogel, and A. Bisno, eds. ASM Press, Washington D. C., p. 173-209.
32. Kilgus, D. J., D. J. Howe, and A. Strang. 2002. Results of periprosthetic hip and knee infections caused by resistant bacteria. Clin. Orthop. Relat. Res. 404:116-124.
33. Volin, S. J., S. H. Hinrichs, and K. L. Garvin. 2004. Two-stage reimplantation of total joint infections: a comparison of resistant and non-resistant organisms. Clin. Orthop. Relat. Res. 427:94-100.
34. Diwanji, S. R., I. K. Kong, Y. H. Park, S. G. Cho, E. K. Song, and T. R. Yoon. 2008. Two-stage reconstruction of infected hip joints. J. Arthroplasty 23:656-661.
35. Sherman, S. L., K. P. Cunneen, S. Walcott-Sapp, B. Brause, and G. H. Westrich. 2008. Custom total femur spacer and second-stage total femur arthroplasty as a novel approach to infection and periprosthetic fracture. J. Arthroplasty 23:781-786.
36. Bernthal, N. M., A. I. Stavrakis, F. Billi, J. S. Cho, T. J. Kremen, S. I. Simon, A. L. Cheung, G. A. Finerman, J. R. Lieberman, J. S. Adams, and L. S. Miller. 2010. A mouse model of post-arthroplasty Staphylococcus aureus joint infection to evaluate in vivo the efficacy of antimicrobial implant coatings. PLoS One 5. Available at: http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0012580.
37. Greten, T. F., M. P. Manns, and F. Korangy. 2011. Myeloid derived suppressor cells in human diseases. Int. Immunopharmacol. 11:802-807.
38. Talmadge, J. E., and D. I. Gabrilovich. 2013. History of myeloid-derived suppressor cells. Nat. Rev. Cancer 13:739-752.
39. Afkarian, M., J. R. Sedy, J. Yang, N. G. Jacobson, N. Cereb, S. Y. Yang, T. L. Murphy, and K. M. Murphy. 2002. T-bet is a STAT1-induced regulator of IL-12R expression in naive CD4+ T cells. Nat. Immunol. 3:549-557.
40. Gately, M. K., L. M. Renzetti, J. Magram, A. S. Stern, L. Adorini, U. Gubler, and D. H. Presky. 1998. The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses. Annu. Rev. Immunol. 16:495-521.
41. O'Garra, A., N. Hosken, S. Macatonia, C. A. Wenner, and K. Murphy. 1995. The role of macrophage- and dendritic cell-derived IL12 in Th1 phenotype development. Res. Immunol. 146:466-472.
42. Hsieh, C. S., S. E. Macatonia, C. S. Tripp, S. F. Wolf, A. O'Garra, and K. M. Murphy. 1993. Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science 260:547-549.
43. Gabrilovich, D. I., S. Ostrand-Rosenberg, and V. Bronte. 2012. Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 12:253-268.
44. Condamine, T., and D. I. Gabrilovich. 2011. Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. Trends Immunol. 32:19-25.
45. Vignali, D. A., and V. K. Kuchroo. 2012. IL-12 family cytokines: immunological playmakers. Nat. Immunol. 13:722-728.
46. Pulido, L., E. Ghanem, A. Joshi, J. J. Purtill, and J. Parvizi. 2008. Periprosthetic joint infection: the incidence, timing, and predisposing factors. Clin. Orthop. Relat. Res. 466:1710-1715.
47. Fitzpatrick, F., H. Humphreys, and J. P. O'Gara. 2005. The genetics of staphylococcal biofilm formation-will a greater understanding of pathogenesis lead to better management of device-related infection? Clin. Microbiol. Infect. 11:967-973.
48. Kurtz, S., K. Ong, E. Lau, F. Mowat, and M. Halpern. 2007. Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. J. Bone Joint Surg. Am. 89:780-785.
49. Teterycz, D., T. Ferry, D. Lew, R. Stern, M. Assal, P. Hoffmeyer, L. Bernard, and I. Uckay. 2010. Outcome of orthopedic implant infections due to different staphylococci. Int. J. Infect. Dis. 14. Available at: http://www.ijidonline.com/article/S1201-9712 (10) 02436-7/abstract.
50. Cui, Q., W. M. Mihalko, J. S. Shields, M. Ries, and K. J. Saleh. 2007. Antibioticimpregnated cement spacers for the treatment of infection associated with total hip or knee arthroplasty. J. Bone Joint Surg. Am. 89:871-882.
51. Chiu, F. Y., and C. F. Lin. 2009. Antibiotic-impregnated cement in revision total knee arthroplasty: a prospective cohort study of one hundred and eighty-three knees. J. Bone Joint Surg. Am. 91:628-633.
52. Shaw, A. C., D. R. Goldstein, and R. R. Montgomery. 2013. Age-dependent dysregulation of innate immunity. Nat. Rev. Immunol. 13:875-887.
53. Montecino-Rodriguez, E., B. Berent-Maoz, and K. Dorshkind. 2013. Causes, consequences, and reversal of immune system aging. J. Clin. Invest. 123:958-965.
54. Abdi, K., N. J. Singh, E. Spooner, B. M. Kessler, S. Radaev, L. Lantz, T. S. Xiao, P. Matzinger, P. D. Sun, and H. L. Ploegh. 2014. Free IL-12p40 monomer is a polyfunctional adaptor for generating novel IL-12-like heterodimers extracellularly. J. Immunol. 192:6028-6036.
55. Solito, S., L. Pinton, V. Damuzzo, and S. Mandruzzato. 2012. Highlights on molecular mechanisms of MDSC-mediated immune suppression: paving the way for new working hypotheses. Immunol. Invest. 41:722-737.
56. Katoh, H., D. Wang, T. Daikoku, H. Sun, S. K. Dey, and R. N. Dubois. 2013. CXCR2-expressing myeloid-derived suppressor cells are essential to promote colitis-associated tumorigenesis. Cancer Cell 24:631-644.
57. Highfill, S. L., Y. Cui, A. J. Giles, J. P. Smith, H. Zhang, E. Morse, R. N. Kaplan, and C. L. Mackall. 2014. Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy. Sci. Transl. Med. 6. Available at: http://stm. sciencemag.org/content/6/237/237ra67.short.
58. Norris, B. A., L. S. Uebelhoer, H. I. Nakaya, A. A. Price, A. Grakoui, and B. Pulendran. 2013. Chronic but not acute virus infection induces sustained expansion of myeloid suppressor cell numbers that inhibit viral-specific T cell immunity. Immunity 38:309-321.
59. Lesokhin, A. M., T. M. Hohl, S. Kitano, C. Cortez, D. Hirschhorn-Cymerman, F. Avogadri, G. A. Rizzuto, J. J. Lazarus, E. G. Pamer, A. N. Houghton, et al. 2012. Monocytic CCR2 (+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment. Cancer Res. 72:876-886.
60. Huang, B., Z. Lei, J. Zhao, W. Gong, J. Liu, Z. Chen, Y. Liu, D. Li, Y. Yuan, G. M. Zhang, and Z. H. Feng. 2007. CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers. Cancer Lett. 252:86-92.
61. Mao, Y., I. Poschke, E. Wennerberg, Y. Pico De Coaña, S. Egyhazi Brage, I. Schultz, J. Hansson, G. Masucci, A. Lundqvist, and R. Kiessling. 2013. Melanoma-educated CD14+ cells acquire a myeloid-derived suppressor cell phenotype through COX-2-dependent mechanisms. Cancer Res. 73:3877-3887.
62. Obermajer, N., J. L. Wong, R. P. Edwards, K. Odunsi, K. Moysich, and P. Kalinski. 2012. PGE (2)-driven induction and maintenance of cancerassociated myeloid-derived suppressor cells. Immunol. Invest. 41:635-657.
63. Sinha, P., V. K. Clements, A. M. Fulton, and S. Ostrand-Rosenberg. 2007. Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res. 67:4507-4513.
64. Fujita, M., G. Kohanbash, W. Fellows-Mayle, R. L. Hamilton, Y. Komohara, S. A. Decker, J. R. Ohlfest, and H. Okada. 2011. COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells. Cancer Res. 71:2664-2674.
65. Cuenca, A. G., M. J. Delano, K. M. Kelly-Scumpia, C. Moreno, P. O. Scumpia, D. M. Laface, P. G. Heyworth, P. A. Efron, and L. L. Moldawer. 2011. A paradoxical role for myeloid-derived suppressor cells in sepsis and trauma. Mol. Med. 17:281-292.
66. Brudecki, L., D. A. Ferguson, C. E. McCall, and M. El Gazzar. 2012. Myeloidderived suppressor cells evolve during sepsis and can enhance or attenuate the systemic inflammatory response. Infect. Immun. 80:2026-2034.
67. Gabrilovich, D. I., and S. Nagaraj. 2009. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9:162-174.
68. Sinha, P., V. K. Clements, S. K. Bunt, S. M. Albelda, and S. Ostrand-Rosenberg. 2007. Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J. Immunol. 179:977-983.
69. Ostrand-Rosenberg, S., P. Sinha, D. W. Beury, and V. K. Clements. 2012. Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune. Semin. Cancer Biol. 22:275-281.